These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19042984)

  • 21. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
    Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
    Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumour markers].
    Lamerz R; Stieber P
    Dtsch Med Wochenschr; 2004 Dec; 129(50):2722-30. PubMed ID: 15592974
    [No Abstract]   [Full Text] [Related]  

  • 24. [Use of radioimmunoanalysis for tumor markers in the diagnosis of carcinoma of the testes and prostate].
    Kausitz J
    Bratisl Lek Listy; 1988 Oct; 89(10):715-24. PubMed ID: 2463063
    [No Abstract]   [Full Text] [Related]  

  • 25. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
    Canil CM; Tannock IF
    Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
    Cole LA; Nam JH
    Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical use of tumor makers in select cancers: are you confident enough to discuss them with your patients?
    Sanchez Yamamoto D; Hallquist Viale P; Roesser K; Lin A
    Oncol Nurs Forum; 2005 Sep; 32(5):1013-22; quiz 1023-4. PubMed ID: 16136199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum and cellular biologic tumor markers in patients with urologic cancer.
    Javadpour N
    Hum Pathol; 1979 Sep; 10(5):557-68. PubMed ID: 93569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Association of Digit Ratio (2D : 4D) with Cancer: A Systematic Review and Meta-Analysis.
    Bunevicius A
    Dis Markers; 2018; 2018():7698193. PubMed ID: 29581795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
    Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
    Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biological markers of cancer. Critical study].
    Bellet D; Bidart JM
    Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
    Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
    J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
    Bantis A; Grammaticos P
    Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testicular Germ Cell Tumors: Serological and Immunohistochemical Diagnosis.
    Damjanov I
    Acta Med Acad; 2021 Apr; 50(1):58-70. PubMed ID: 34075764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
    Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
    Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.
    Peters IT; Hilders CG; Sier CF; Vahrmeijer AL; Smit VT; Baptist Trimbos J; Kuppen PJ
    Arch Gynecol Obstet; 2016 Aug; 294(2):385-93. PubMed ID: 26946151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practice guidelines for tumor marker use in the clinic.
    Sturgeon C
    Clin Chem; 2002 Aug; 48(8):1151-9. PubMed ID: 12142367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
    Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.